Le Lézard
Classified in: Health, Science and technology
Subject: ACC

Cantargia publishes interim report for first quarter 2022


STOCKHOLM, May 23, 2022 /PRNewswire/ -- Cantargia AB's ("Cantargia") interim report for first quarter 2022 is now available on the company's web page www.cantargia.com/en/investors/financial-reports.

Significant events in the first quarter           

Significant events after the end of the period          

Financial information

First Quarter 2022      

  •  Net sales: SEK 0 M (0)                                               
  •  Operating loss: SEK -121.6 M (-73.2)                                               
  •  Loss after tax: SEK -117.5 M (-72.6)                                               
  •  Loss per share: before and after dilution, SEK -1.17 (-0.72)                                               
  •  Equity/assets ratio: 82 (94) per cent
  •  Cash and cash equivalents: SEK 205.7 M (176.4)
  •  Short-term investments: SEK 237.1 M (666.0)

In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on May 23, at 10:00 a.m. CET, where Göran Forsberg, CEO, and Bengt Jöndell, CFO, will present Cantargia and comment on the quarterly report for the first quarter 2022, followed by a Q&A-session.

The conference call can be followed at: https://tv.streamfabriken.com/cantargia-q1-2022

To attend through telephone, please dial-in at one of the numbers below:

SE: +46856642704
UK: +443333009265
US: +16467224904

The webcast will also be available on demand on Cantargia's corporate website: www.cantargia.com

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com

This is information that Cantargia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on May 23, 2022.

About Cantargia

Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The lead project, the antibody nadunolimab (CAN04), is being studied clinically in combination with chemotherapy or immune therapy in a series of clinical studies ? CANFOUR, CIRIFOUR, CAPAFOUR, CESTAFOUR and TRIFOUR ? with a primary focus on non-small cell lung cancer and pancreatic cancer. Positive interim data from the combination with chemotherapy indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second project, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/cantargia-ab/r/cantargia-publishes-interim-report-for-first-quarter-2022,c3571553

The following files are available for download:

https://mb.cision.com/Main/7470/3571553/1582634.pdf

Interim report Q1 2022 final

https://mb.cision.com/Public/7470/3571553/ba2243d8960b3b57.pdf

Interim report Q1 2022 PR 220523 Eng Final


These press releases may also interest you

at 06:05
Ondat, the leading Kubernetes-native data platform provider, today released into general availability version 2.8 of its Ondat platform for stateful workloads in Kubernetes. The new version brings significant changes that open up the option of...

at 06:05
OrbitalRX announced today it has joined a new coalition of diverse stakeholders to address drug shortages in the United States. The End Drug Shortages Alliance provides a forum for key stakeholders to take strategic aim at one of health care's more...

at 06:05
Vizient, Inc. announced today it has entered into a strategic partnership with Supply Risk Solutions to provide a database platform for the collection of healthcare supply pedigree data. The partnership will provide automated supply chain disruption...

at 06:05
Token, a revolutionary provider of secure, wearable authentication solutions, today announced a $13 million financing round and the appointment of John Gunn as the company's CEO. Token will use the funds to increase its investment in solution...

at 06:05
Energous Corporation , a leading developer of RF-based charging for wireless power networks, and Atmosic Technologies, an innovator in energy harvesting wireless System-on-Chips (SoCs) and modules for the Internet of Things (IoT), today announced...

at 06:05
NoRedInk, a provider of adaptive online writing curriculum used in more than 60% of U.S. school districts, now integrates with Schoology Learning, the leading K-12-focused learning management system (LMS) and a central part of the PowerSchool Unified...



News published on 23 may 2022 at 02:48 and distributed by: